Zogenix (ZGNX) Tops Q1 EPS by 20c

Zogenix (NASDAQ: ZGNX) reported Q1 EPS of ($0.42), $0.20 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $9.2 million versus the consensus estimate of $4.9 million.

2016 Financial Guidance

Zogenix is reiterating its previously provided financial guidance for the full year 2016.

• Research and development expenses are expected to be $54-59 million, reflecting initiation and ramp-up of ZX008 clinical studies;
• Selling, general and administrative expenses are expected to be $25-27 million; and
• Contract manufacturing revenue from the supply of Sumavel DosePro to Endo is expected at a low single-digit markup over cost of contract manufacturing.

For earnings history and earnings-related data on Zogenix (ZGNX) click here.

You May Also Be Interested In

• MFA Financial (MFA) Misses Q3 EPS by 2c
• Harmony Biosciences (HRMY) Misses Q3 EPS by 30c; Offers Guidance
• Reservoir Media, Inc. (RSVR) Tops Q2 EPS by 2c; offers guidance